THE EVALUATION OF AMINOTRANSFERASES ENZYME LEVELS IN HEPATITIS C PATIENTS
DOI:
https://doi.org/10.71000/wx57q261Keywords:
Alanine Transaminase, , Aminotransferases, Aspartate Transaminase, Chronic Hepatitis C, Enzyme Levels, Hepatocellular Injury, Liver Function TestsAbstract
Background: Hepatitis C virus (HCV) is a major cause of chronic liver disease worldwide, leading to complications such as fibrosis, cirrhosis, and hepatocellular carcinoma. Serum aminotransferase levels, particularly alanine aminotransferase (ALT) and aspartate aminotransferase (AST), remain essential biochemical markers for assessing hepatocellular injury. While ALT is more liver-specific, AST may also rise in extrahepatic conditions, making their combined interpretation valuable for evaluating disease progression and severity in chronic HCV.
Objective: To assess ALT and AST levels in patients with chronic HCV and examine gender-based variations in enzyme profiles.
Methods: This retrospective observational study included 110 HCV-positive patients aged 20–87 years, comprising 67 males (60.9%) and 43 females (39.1%). Serum samples were analyzed for ALT and AST activity using Sigma Aldrich alanine aminotransferase and aspartate aminotransferase activity assay kits. Descriptive statistics were calculated, and gender-based differences were assessed using independent t-tests, with significance set at p ≤ 0.05.
Results: The overall mean ALT level was 61.8 ± 26.9 U/L (range: 21–119), and the mean AST level was 70.3 ± 22.4 U/L (range: 24–98). ALT levels were higher in males (63.8 ± 25.5 U/L) than females (55.9 ± 28.8 U/L), while AST levels were higher in females (71.6 ± 22.1 U/L) than males (69.4 ± 22.6 U/L). Statistical testing revealed no significant gender difference in ALT (p = 0.094), and AST comparison was inconclusive due to computational issues. Enzyme distribution analysis showed a broader spread in AST levels, indicating heterogeneous liver injury severity among patients.
Conclusion: ALT and AST levels remain critical in monitoring liver function in chronic HCV, with AST predominance suggesting advanced hepatic injury. Regular biochemical monitoring, alongside larger and more diverse patient studies, is recommended to improve diagnostic precision and disease management.
References
Chen TB, Jiang JW, Guo HY, Chen XT, Zhi S, Hu YH, et al. Causal relationship between hepatic function indicators and thrombocytopenia risk in early-stage hepatitis B virus infection: evidence from clinical observational studies and mendelian randomization analyses. Front Immunol. 2025;16:1440317.
Abo El-Khair SM, El-Alfy HA, Elsamanoudy AZ, Elhammady D, Abd-Elfattah N, Eldeek B, et al. Development of a novel glycated protein-based fibrosis prediction score for determination of significant liver fibrosis in HCV-infected patients, a preliminary study. J Med Virol. 2020;92(12):3525-33.
Abdelsameea E, Alsebaey A, Abdel-Razek W, Ehsan N, Morad W, Salama M, et al. Elastography and serum markers of fibrosis versus liver biopsy in 1270 Egyptian patients with hepatitis C. Eur J Gastroenterol Hepatol. 2020;32(12):1553-8.
Elabd WK, Elbakry MMM, Hassany M, Baki AA, Seoudi DM, El Azeem EMA. Evaluation of miRNA-7, miRNA-10 and miRNA-21 as diagnostic non-invasive biomarkers of hepatocellular carcinoma. Clin Exp Hepatol. 2023;9(3):221-7.
WHO Global Hepatitis Report, 2022.
Abdelbary MS, Samir R, El-Nahaas SM, Shahin RMH, El-Sayed M, Gaber Y, et al. Hepatitis B Reactivation Following Eradication of HCV with Direct-Acting Antiviral Drugs (DAAs) in a Cohort of Patients from Different Institutions in Egypt. J Clin Exp Hepatol. 2022;12(5):1276-84.
Liu YC, Jeng WJ, Cheng YT, Hsieh YC, Teng W, Chen YC, et al. Incidence and predictors for abnormal liver function during direct-acting antiviral agents in chronic hepatitis C patients. Medicine (Baltimore). 2020;99(37):e21898.
McLeod A, Hutchinson SJ, Weir A, Barclay S, Schofield J, Frew CG, et al. Liver function tests in primary care provide a key opportunity to diagnose and engage patients with hepatitis C. Epidemiol Infect. 2022;150:e133.
de Faria AGA, Chaves FC, Ferraz MLG, Andrade LEC. Selective decrease in complement C2 hemolytic activity is a sensitive marker for cryoglobulinemia and active disease in hepatitis C patients. Dig Liver Dis. 2021;53(7):860-5.
Mohamed AA, Omran D, El-Feky S, Darwish H, Kassas A, Farouk A, et al. Toll-like receptor 7 mRNA is reduced in hepatitis C-based liver cirrhosis and hepatocellular carcinoma, out-performs alpha-fetoprotein levels, and with age and serum aspartate aminotransferase is a new diagnostic index. Br J Biomed Sci. 2021;78(1):18-22.
Uzlova N, Mnozil Stridova K, Merta D, Rychlik I, Frankova S. Transient Elastography as the First-Line Assessment of Liver Fibrosis and Its Correlation with Serum Markers. Medicina (Kaunas). 2023;59(4).
Taghinejad A, Barani S, Gholijani N, Ghandehari F, Khansalar S, Asadipour M, et al. Variations in IL-22, IL-27 and IL-35 serum levels in untreated and treated hepatitis C patients. Eur Cytokine Netw. 2020;31(4):134-9.
Nakajima T, Karino Y, Hige S, Suii H, Tatsumi R, Yamaguchi M, et al. Factors affecting the recovery of hepatic reserve after sustained virologic response by direct-acting antiviral agents in chronic hepatitis C virus-infected patients. J Gastroenterol Hepatol. 2021;36(2):367-75.
Polaris Observatory HCV Collaborators. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: A modelling study. Lancet Gastroenterol. Hepatol. 2022, 7, 396–415.
Roudot-Thoraval, F. Epidemiology of hepatitis C virus infection. Clin. Res. Hepatol. Gastroenterol. 2021, 45, 101596.
Martinello, M.; Solomon, S.S.; Terrault, N.A.; Dore, G.J. Hepatitis C. Lancet 2023, 402, 1085–1096.
Manns, M.P.; Maasoumy, B. Breakthroughs in hepatitis C research: From discovery to cure. Nat. Rev. Gastroenterol. Hepatol. 2022, 19, 533–550.
Artenie, A.; Stone, J.; Fraser, H.; Stewart, D.; Arum, C.; Lim, A.G.; McNaughton, A.L.; Trickey, A.; Ward, Z.; Abramovitz, D.; et al. HIV and HCV Incidence Review Collaborative Group. Incidence of HIV and hepatitis C virus among people who inject drugs, and associations with age and sex or gender: A global systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 2023, 8, 533–552.
Kumar R, et al. ALT and AST Levels in Chronic HCV Infection. J Med Virol. 2021;93(5):2619–2626.
Goyal A, et al. Correlation of Liver Enzymes with HCV Viral Load in Indian Patients. J Clin Exp Hepatol. 2022;12(3):201–207.
Ahmad I, et al. Association of Elevated Liver Enzymes with HCV Viral Load. J Med Virol. 2020;92(5):761–768.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Mohsin Majeed, Muhammad Lubaba Bin Ubaid, Rimsha Zulfiqar, Muhammad Masoom Amin, Ramaz Rashid, Rimal Rashid, Waqas Mahmood, Yawar Abbas Siyal, Muhammad Mudasir Atta, Ayesha Nazir (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
